TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant must be greater than or equal to (≥)18 years of age;~* Participant must be enrolled in Study AG348-C-008.~Exclusion Criteria:~- Participant is enrolled in an Agios-sponsored clinical study involving treatment with a pyruvate kinase activator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PK Deficiency Diagnosed (Type: None): Participants previously diagnosed with PK deficiency in Study AG348-C-008 (NCT03481738), will receive routine clinical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Meets entry criteria for high risk~Exclusion Criteria~* Evidence of active invasive fungal infection~* Received more than one dose of systemic antifungal agent within 72 hours prior to first dose of study drug~* Known to be HIV positive who have CD4 count less than 500 cells/mm3~* Has life-expectancy of less than 72 hours or moribund

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be a single-organ recipient (kidney only)~* Participants who are receiving their first living donor or deceased donor transplant~Exclusion Criteria:~* Participants who are recipients of HLA-identical living-donor renal transplants~* Participants with a PRA value \> 10% within 30 days prior to the transplant~* Participants who have received a multi-organ transplant~* Participants who are who are positive for hepatitis C, hepatitis B surface antigen or HIV~* Participants who have received an investigational drug within 6 weeks of study entry~* Participants who have a previous history of, or who currently have, malignancies and/or lymphoma~* Participants who have received corticosteroids within three months of transplantation~* Participants who are 3rd transplant recipients~* Female participants who are pregnant or lactating. Fertile female participants who are sexually active must agree to use an acceptable method of birth control during the study

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Campath 1-H (Type: EXPERIMENTAL): Campath 1-H

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years old~* Provided written consent for participation in the trial prior to any study-specific procedures or requirements~* Posterior uveitis or panuveitis associated with macular oedema defined as increased macular thickness (more than 250 mm assessed by Stratus TD-OCT or 300 mm with Cirrus SD-OCT ) and/or the presence of cystoid spaces in the macula, and the absence of epiretinal membranes.~* Patient with oral contraception~* Posterior uveitis or panuveitis associated with macular oedema~* Patients with histologically proven sarcoidosis or a presumed sarcoidosis. In case of a non caseating granuloma in biopsy tissues, the patients with presumed sarcoidosis meet at least 2 of the 4 following criteria: typical changes on chest radiography and computed tomography; predominantly CD4 lymphocytosis in bronchoalveolar lavage (BAL) fluid; elevated serum ACE levels; elevated gallium or 5 fluorodeoxyglucose uptake~Exclusion Criteria:~* Patients who do not fulfill the inclusion criteria~* Other causes of uveitis~* Extra ophthalmologic manifestations of sarcoidosis justifying corticosteroids~* Patients previously treated with immunosuppressive agents or corticosteroids of more than 10 mg daily over 15 days.~* Patients with life-threatening conditions~* Chronic hepatopathy or renal failure~* Uncontrolled diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methotrexate (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CRT In Narrow QRS Heart Failure: Mechanistic Insights From Cardiac MRI And Electroanatomical Mapping

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Participant is willing and able to give informed consent for participation in the study.~  * Male or Female, aged 18 years or above.~ * NYHA grade III-IV heart failure~ * LVEF\<35%~ * QRS duration \<120ms~ * On optimum medical therapy for heart failure~ * Female participants of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter~ * Able (in the Investigators opinion) and willing to comply with all study requirements.~ * Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.~Exclusion Criteria:~* • Female participants who is pregnant, lactating or planning pregnancy during the course of the study.~  * Scheduled elective surgery or other procedures requiring general anaesthesia during the study.~ * Participant who is terminally ill or is inappropriate for placebo medication~ * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.~ * Contraindication to an MRI scan~ * Rate uncontrolled atrial fibrillation precluding a cMR~ * Significant peripheral vascular disease precluding an EP study~ * A contraindication to anticoagulation~ * A prosthetic aortic or tricuspid valve~ * Significant Aortic valve disease~ * Known LV thrombus~ * Insufficient capacity to consent to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mechanical Dyssynchrony (Type: ACTIVE_COMPARATOR): Those with cardiac MRI evidence of mechanical dyssynchrony
- No Mechanical Dyssynchrony (Type: ACTIVE_COMPARATOR): Those without mechanical dyssynchrony on cardiac MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Water-based Zinc Intervention Trial in Zinc Deficient Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 2-5 year old children~* subjects residing in the study area for the whole study period~Exclusion Criteria:~* subject with severe anemia (Hb \< 7 g/dl)~* subjects affected by chronic medical illnesses known to interact with zinc metabolism~* subjects receiving zinc supplementation or other medicines that may affect zinc metabolism

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- intervention filter (Type: EXPERIMENTAL): children consuming purified and zinc enriched water delivered by a household-based water filter
- placebo filter (Type: PLACEBO_COMPARATOR): children consuming purified water delivered by a household-based water filter
- disinfection tablets (Type: ACTIVE_COMPARATOR): children will consume water treated with government promoted disinfection tablets (aquatabs)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Pain After Surgical Intensive Care Admission: Incidence and Risk Factors: the DOLOCHROREA Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Admission in the surgical critical care unit of the University Hospital of Besançon from February 2015~* Age over 18 yr old~* Informed consent~Exclusion Criteria:~* Age under 18 yr old~* Death within the first 6 months after the end of the stay in the surgical intensive unit of the University Hospital of Besançon~* Glasgow Coma Score under 8 at admission and/or at discharge~* Planned admission after elective surgery~* Medical history of cognitive disorder~* Refuse to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Abdominal Binder Use on Postoperative Pain and Mobility in Patients Undergoing Pelvic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years or older.~* Willing and able to provide informed consent.~* Patients must be undergoing scheduled pelvic surgery.~* Patients must be admitted overnight (at least one night) after surgery.~Exclusion Criteria:~* Patients who are younger than 18 years old.~* Patients who are unable or unwilling to provide informed consent.~* Patients who are illiterate.~* Patients who are non-English speaking or reading.~* Patients who are unwilling to be contacted by phone after surgery.~* Patients who are undergoing pelvic surgery that does not warrant observation or admission after surgery for at least one night.~* Patients who are having surgery for any other indication other than pelvic surgery.~* Patients with a chronic pain syndrome (as evidenced by daily intake of opioids).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control / No Binder (Type: NO_INTERVENTION): Patients randomized to routine care / no abdominal binder use will not use an abdominal binder during their post operative course.
- Abdominal binder (Type: EXPERIMENTAL): Patients randomized abdominal binder use will have an abdominal binder placed on them in the operating room once their surgery has been completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects scheduled for any surgical procedure under general anesthesia or combined general-regional anesthesia, with the exception of open-heart or intracranial surgery. Regional anesthesia includes: 1) Epidural anesthesia, 2) Sub-arachnoid block (spinal), or 3)any regional nerve block~2. Anticipated postoperative hospital admission (defined as at least one overnight hospital stay)~Exclusion Criteria:~Veterans will be excluded if:~1. They are on beta blocker therapy at the time of the preoperative baseline assessment~2. They report sensitivity or allergies to propranolol, or a history of PTSD exacerbation with prior propranolol therapy~3. Veterans who fulfill the AHA/ACC level I recommendation criteria for perioperative beta blocker therapy (e.g., metoprolol, atenolol) and should not be randomized to placebo group~4. Medical exclusions criteria: high grade heart block without pacemaker (all patients with 2nd and 3rd degree heart block), marked resting bradycardia (heart rate ≤ 55 beats per minute), blood pressure \< 100 mmHg, uncompensated congested heart failure, severe hyperactive airway disease, and Raynaud's disease~5. Pregnancy~6. Current use of medication that may involve potentially dangerous interaction with propranolol~7. Circumstances that, in the opinion of the principal investigator, would preclude participation in a study of this type (e.g. medical concerns or difficulty in long-term followup).~8. Open-heart surgery and intracranial surgery

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propranolol Hydrochloride (Type: EXPERIMENTAL): None
- Placebo Group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Experimental Tobacco Marketplace in Regulating Flavored Tobacco Products in Menthol Cigarette Smokers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Menthol cigarette smokers who report smoking a brand that has a non-menthol equivalent.~* Residing in Western New York.~* Voluntarily provide informed consent to participate in the study.~Exclusion Criteria:~* Any known history of macular degeneration, glaucoma, cataracts, eye implant, permanently dilated pupils or the use of a screen reader/magnifier.~* The following special populations will not be included:~  * Adults unable to consent~ * Individuals who are not yet adults (infants, children, teenagers)~ * Prisoners~ * Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Prevention (Type: EXPERIMENTAL): During the session, participants are presented with randomly ordered conditions: menthol cigarettes and five flavored e-cigarettes (menthol/mint, fruits, sweets, alcohol, snacks/meals), menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes, non-menthol cigarettes and five flavored e-cigarettes, and non-menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes. Participants' visual attention is evaluated by eye-tracking equipment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the current ESC Guidelines or ACCF/AHA/HRS Class I or Class IIa indications for CRT implant (including upgrades from single or dual chamber ICDs)~* Must be willing and able to comply with study requirements~* Must indicate their understanding of the study and willingness to participate by signing an appropriate informed consent form~Exclusion Criteria:~* Already had a CRT device implanted~* Myocardial Infarction, unstable angina within 40 days prior the enrollment~* Recent cardiac revascularization (PTCA, Stent or CABG) in the 4 weeks prior to enrollment or planned for the 3 months following~* Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) in the 3 months prior the enrollment~* Primary valvular disease~* Atrial Fibrillation:~  * Persistent AF at the time of enrollment~ * Permanent AF not treated with AV node ablation within 2 weeks from the CRT implant~ * History or incidence of Paroxysmal or Persistent AF within 30 days prior the enrollment~* Unable to comply with the follow up schedule~* Less than 18 years of age~* Pregnant or are planning to become pregnant during the duration of the investigation~* Classification of Status 1 for cardiac transplantation or consideration for transplantation over the next 12 months~* Undergone a cardiac transplantation~* Life expectancy \< 12 months~* Currently participating in any other clinical investigation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MPP ON (Type: EXPERIMENTAL): MPP ON: feature is enabled
- MPP OFF (Type: NO_INTERVENTION): MPP OFF: feature not enabled

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 18 years at time of informed consent.~* Previous histologically confirmed diagnosis of RCC or NSCLC having received previously checkpoint inhibitors as part of a SoC regimen.~* Consent to mandatory paired tumour biopsies of at least one tumour site accessible for repeat biopsies. Planned sites for tumour biopsies must not have been previously irradiated and could be a target lesion of \>2 cm diameter according to RECIST v1.1 and must be approved on a case-by-case basis by the Sponsor.~* Measurable disease as per RECIST v1.1 and documented by computed tomography (CT) and/or magnetic resonance imaging (MRI).~Exclusion Criteria:~* Any anti-tumour therapy, including investigational therapies, within 4 weeks prior to the first dose of EXS21546.~* Unresolved or unstable serious toxic side-effects of prior chemotherapy or radiotherapy, i.e., ≥ Grade 2 per CTCAE v5.0.~* Concurrent other malignancy that could interfere with response evaluation.~* Symptomatic central nervous system (CNS) malignancy or metastases. Screening of symptomatic participants without history of CNS metastases is not required. Participants with asymptomatic CNS lesions should have completed standard therapy for their CNS lesions 60 days prior to study enrolment.~* History of interstitial lung disease and/or prior immunotherapy-related pneumonitis.~* Patients who have had or are scheduled to have major surgery \< 28 days prior to the first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EXS21546 (Type: EXPERIMENTAL): EXS21546 Granule in Capsule for oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients PCOS (Rotterdam ESHRE / ASRM criteria)~Combination of at least two of the following three criteria:~* Cycle disorder~* Clinical hyperandrogenism and / or biological~* Account antral follicles\> 24~* Age ≤ 18 ≤ 38 years~* BMI \<35 kg / m²~* Able to understand the protocol and signed informed consent~Exclusion Criteria:~* Patients not having the Rotterdam criteria~* Patients\> 38 years and / or BMI\> 35 kg / m²~* Woman enjoying a measure of legal protection~* Hypersensitivity to any component of the Inofolic (myo-inositol, soy, folic acid, glycerol, gelatin, coloring E171)~* Participation in another interventional biomedical research with treatment administered may disrupt ovarian stimulation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Inofolic® (Type: EXPERIMENTAL): standard ovarian stimulation and Inofolic®
- Gonadotropins;Folic Acid (Type: ACTIVE_COMPARATOR): standard ovarian stimulation without Inofolic®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Risk Stratification for Patients Presenting With Acute Pulmonary Embolism (PE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old~* Acute PE (diagnosed by pulmonary angiogram, Computed tomography using the DVT/PE protocol, Ventilation/Perfusion (V/Q) scan read as high probability by the radiologist, or (+) lower extremity Doppler ultrasound with symptoms consistent with PE)~Exclusion Criteria:~* Hemodynamic instability (BP \< 90/60, IV pressor support) on admission~* Acute respiratory failure on admission~* Treatment with thrombolytic therapy prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients diagnosed with acute pulmonary embolism were enrolled in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues